Curis, Genentech, Roche sales and marketing update

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in a second early benefit assessment that added benefit for Erivedge vismodegib from Roche is “not proven” vs. comparator therapy to treat locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC -- its approved indication. In 2014, Germany’s Federal Joint Committee (G-BA) said in a final benefit assessment that Erivedge has “marginal” additional benefit over best supportive care (BSC) in patients with locally advanced BCC for whom both surgery and radiotherapy are considered inappropriate. G-BA limited the 2014 decision to two years (see BioCentury, Feb. 10, 2014). ...